Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL4036904 | 0.91 | TSHR (0.58) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| Tetrahydrofuran SCHEMBL2502942 | 0.91 | TSHR (0.64) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL4977794 | 0.85 | TSHR (0.56) | TSHRSMN1; SMN2PKMMEN1KMT2A | |
| Morpholine SCHEMBL3316539 | 0.85 | TSHR (0.56) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL21064874 | 0.84 | TSHR (1.00) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL19193 | 0.84 | — | — | |
| Cyclohexane SCHEMBL6963396 | 0.81 | TSHR (0.82) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| Cyclohexane SCHEMBL1659384 | 0.81 | TSHR (0.82) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL2354786 | 0.81 | TSHR (0.64) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL4431010 | 0.81 | TSHR (0.93) | TSHRSMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284153-A1 | CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-19 | — | — | US | claimed |
| EP-3498704-A1 | CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-10822319-B2 | Crystal of DPP-IV long-acting inhibitor and salt | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20190284153-A1 | CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| EP-3498704-A1 | CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-8916581-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-1928882-B1 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARM INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2450360-A2 | (S)-N-Methylnaltrexone | Progenics Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2387400-A1 | NOVEL FORMS OF BENDAMUSTINE FREE BASE | Cephalon, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8037645-B2 | Trellis and accent band | DIVISION 8 PRODUCTS, INC. | 2011-10-18 | — | — | US | disclosed |
| US-8003794-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100105911-A1 | (S)-N-methylnal trexone | ALBANY MOLECULAR RESEARCH, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7563899-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1928882-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070265293-A1 | Opioid antagonists; lyophilization | PROGENICS PHARMACEUTICAIS, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2006127898-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284153-A1 | CRYSTAL OF DPP-IV LONG-ACTING INHIBITOR AND SALT | DPP4, DPP9, DPP7 | TSHR 2570/4885SMN1; SMN2 3538/4885CHRM2 4637/4885 |
| US-10822319-B2 | Crystal of DPP-IV long-acting inhibitor and salt | DPP4, DPP7, DPP9 | TSHR 2537/4885SMN1; SMN2 3541/4885CHRM2 4614/4885 |
| US-20100105911-A1 | (S)-N-methylnal trexone | TSNAX, MTX1, MTX2 | TSHR 1371/4885SMN1; SMN2 13/4885CHRM2 1075/4885 |
| US-20070265293-A1 | Opioid antagonists; lyophilization | OPRM1, OGFR, OPRL1 | TSHR 1691/4885SMN1; SMN2 61/4885CHRM2 449/4885 |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | OPRM1, OPRL1, LPXN | TSHR 1450/4885SMN1; SMN2 34/4885CHRM2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.